How does urine drug testing work?
Urine drug testing is a two-step process: an initial Immunoassay screen flags samples that are "non-negative," and a confirmation test using GC-MS (gas chromatography–mass spectrometry) or LC-MS/MS (liquid chromatography–tandem mass spectrometry) identifies the specific analyte above a defined Cutoff level . For federally regulated programs, a licensed Medical Review Officer (MRO) reviews any non-negative result with the donor before reporting it as verified. Detection windows range from about 1–3 days for most drugs to several weeks for chronic cannabis use.
What urine tests detect
Urine is the most widely used specimen for drug testing because it offers a useful balance of detection window, collection ease, cost, and laboratory infrastructure. The federal panel — used under SAMHSA Mandatory Guidelines and 49 CFR Part 40 — currently includes THC, cocaine, opioids (with semi-synthetics), fentanyl and norfentanyl (added July 7, 2025), amphetamines (with MDMA/MDA), and PCP. Non-federal employer panels commonly mirror this composition or add benzodiazepines, barbiturates, methadone, and additional opioids (the "10-panel").
Most urine assays target a Metabolite — a compound produced by metabolism of the parent drug. The most familiar example is THC-COOH (the inactive metabolite of cannabis), which is fat-soluble and accumulates in chronic users, producing a notably long detection window. Tests for cocaine target benzoylecgonine; opioid testing targets morphine, codeine, and 6-acetylmorphine (a heroin-specific marker).
Detection windows in urine
Urine detection windows are approximate and depend on the substance, dose, frequency of use, individual physiology, hydration, and the laboratory's cutoff. As a rough guide:
- 1–3 days for most substances after a single use (cocaine, amphetamines, heroin metabolites, single THC use).
- Up to 1 week for chronic stimulant use and many opioids.
- Up to 30 days or more for daily, heavy cannabis use (THC-COOH).
- Up to ~80 hours for EtG (a conjugated alcohol metabolite) — useful in abstinence monitoring.
For an interactive substance-by-substance view, see the Detection Windows Explorer.
Federal cutoff levels
The federal Mandatory Guidelines define screening and confirmation cutoffs for each analyte. Programs that are not federally regulated may use the same or different cutoffs; healthcare and recovery-monitoring programs often use lower cutoffs to detect more subtle use.
| Analyte | Screen | Confirm |
|---|---|---|
| THCA (cannabinoid metabolite) | 50 ng/mL | 15 ng/mL |
| Benzoylecgonine | 150 ng/mL | 100 ng/mL |
| Codeine / morphine / 6-AM | 2000 ng/mL | 2000 ng/mL |
| Hydrocodone / hydromorphone | 300 ng/mL | 100 ng/mL |
| Oxycodone / oxymorphone | 100 ng/mL | 100 ng/mL |
| Fentanyl / norfentanyl | 1 ng/mL | 1 ng/mL |
| Amphetamine / methamphetamine | 500 ng/mL | 250 ng/mL |
| MDMA / MDA | 500 ng/mL | 250 ng/mL |
| Phencyclidine (PCP) | 25 ng/mL | 25 ng/mL |
- Federal panel updated July 7, 2025 to add fentanyl and norfentanyl.
- Oral-fluid testing authorized as a urine alternative in 2023, pending HHS lab certification.
How urine collection works
Under 49 CFR Part 40, urine is collected at a certified collection site with a federally specified chain-of-custody process. The donor enters a private collection room (no water source available, blue toilet water), provides at least 45 mL of specimen, and the collector verifies the temperature within four minutes of collection (90.5°F–99.8°F / 32.5°C–37.7°C). A split-specimen protocol is used: the specimen is split into a Primary (Bottle A) and Split (Bottle B) for separate handling and a possible donor-requested re-test.
The collector and donor each sign the Federal Drug Testing Custody and Control Form (CCF), which travels with the specimen to maintain an unbroken Chain of custody .
Accuracy and limitations
Urine drug testing is highly accurate when performed under SAMHSA-certified laboratory conditions with confirmation testing and MRO review. But a positive urine result has important interpretive limits:
- It is not a measure of impairment. Especially for cannabis, where the urinary metabolite THC-COOH can persist days to weeks after any psychoactive effect ends, the result confirms exposure within a detection window — not current impairment.
- Immunoassay screens can produce false positives. Common cross-reactants include pseudoephedrine (amphetamines), some NSAIDs (cannabinoids — rare), and poppy-seed ingestion (opiates). This is exactly why every non-negative screen is confirmed by mass spectrometry and reviewed by an MRO.
- Specimen integrity matters. Excessively dilute, abnormally warm, or chemically adulterated specimens are flagged by lab integrity testing.
Regulatory currency — 2025 updates
SAMHSA added fentanyl and norfentanyl to the authorized federal urine and oral-fluid panels effective July 7, 2025, reflecting the substance's role in the U.S. overdose crisis. DOT-regulated employers test for fentanyl as of that effective date under 49 CFR Part 40. Earlier, in 2023, DOT authorized oral fluid as an alternative specimen — implementation depends on HHS lab certification.
At a glance: pros and cons
Pros
- Federally approved (SAMHSA / DOT)
- Widely available collection sites
- Several-day detection window for most analytes
- Strong forensic and legal precedent
Limits
- Cannot demonstrate impairment
- Susceptible to dilution / adulteration if collection is unobserved
- Chronic-cannabis windows are very long
- Some immunoassays have known cross-reactivity issues
Frequently asked questions
Urine windows vary by substance and frequency of use. For most drugs, a single use is detectable for 1–3 days; chronic cannabis use can extend to several weeks because THC-COOH is fat-soluble and accumulates. See our detection windows explorer for substance-specific ranges.
Federal workplace urine programs use a 50 ng/mL screening cutoff and a 15 ng/mL confirmation cutoff for THC-COOH. Some non-DOT employers and clinical programs use a lower 20 ng/mL or 15 ng/mL screening cutoff.
Under federal screening cutoffs, exposure to typical real-world secondhand smoke is very unlikely to produce a confirmed positive. Confirmed positives in studies have generally required extreme, enclosed-space exposure.
A non-negative screen is sent to the laboratory for confirmation by GC-MS or LC-MS/MS. If confirmed, the Medical Review Officer (MRO) contacts the donor to identify any legitimate medical explanation before reporting a verified result.
Sources & references
drugtest.co content is sourced from primary regulatory and clinical references. We do not cite gray-market or "how to pass" sources.
- Mandatory Guidelines for Federal Workplace Drug Testing Programs (Urine)
- 49 CFR Part 40 — Procedures for Transportation Workplace Drug and Alcohol Testing Programs
- Final Notice — Addition of Fentanyl and Norfentanyl to Federal Workplace Drug Testing Panels
- Public Policy Statement on Drug Testing in Addiction Treatment